Do You Have Intravenous Trombololitis in Patients on Doax?

The main reason why people fear to use intravenous trombolitic in patients on doax is actually the risk of bleeding. So our secondary endpoint was actually the functional independence at 90 days measured with the modified rankings case score. And we didn't find any statistically significant difference between patients on doAX or patients without doax in terms of functional outcome, which means that the benefits of intravenous t rombolitis seems to be the same for patients onDoax compared to patients without a recent doax intake.